Were Karin Eastham’s Veracyte (VCYT) share sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Karin Eastham on September 5, 2025. Such plans schedule transactions in advance, making the timing more routine and less discretionary.

Veracyte (VCYT) director logs 3,729-share Rule 10b5-1 stock sale

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

VERACYTE, INC. director Karin Eastham reported selling 3,729 shares of common stock on June 18, 2026 in open-market transactions. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 5, 2025, at weighted average prices of $52.78 and $53.55 per share.

Insider Trade Summary 10b5-1

Net Seller: 3,729 shares ($197,234)

Net Sell 2 txns

Insider EASTHAM KARIN

Role null

Sold 3,729 shs ($197K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,200	$52.7832	$169K
Sale	Common Stock	529	$53.5504	$28K

Holdings After Transaction: Common Stock — 15,626 shares (Direct, null)

Footnotes (1)

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $53.29 to $53.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Key Figures

Shares sold: 3,729 shares Sale price block 1: $52.7832 per share Sale price block 2: $53.5504 per share +3 more

6 metrics

Shares sold 3,729 shares Total Veracyte common stock sold on June 18, 2026

Sale price block 1 $52.7832 per share Weighted average price for 3,200 shares sold

Sale price block 2 $53.5504 per share Weighted average price for 529 shares sold

10b5-1 plan adoption date September 5, 2025 Date Karin Eastham adopted the Rule 10b5-1 plan

Price range block 1 $52.26–$53.26 Range of individual sale prices for one transaction set

Price range block 2 $53.29–$53.70 Range of individual sale prices for the other transaction set

Key Terms

Rule 10b5-1 plan, weighted average sales price, open-market sale, Form 4

4 terms

Rule 10b5-1 plan regulatory

"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sales price financial

"Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26."

open-market sale financial

"transaction_action: "open-market sale" with transaction code "S""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/22/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EASTHAM KARIN

(Last)

(First)

(Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		S⁽¹⁾		3,200	D	$52.7832⁽²⁾	15,626	D
Common Stock	06/18/2026		S⁽¹⁾		529	D	$53.5504⁽³⁾	15,097	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025.

2. Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

3. Represents weighted average sales price. Sale prices for the transactions range from $53.29 to $53.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Veracyte (VCYT) disclose for Karin Eastham?

Veracyte disclosed that director Karin Eastham sold 3,729 shares of common stock in open-market transactions on June 18, 2026. The sales were reported on a Form 4 insider filing and executed under a pre-arranged Rule 10b5-1 trading plan.

How many Veracyte (VCYT) shares did Karin Eastham sell and at what prices?

Karin Eastham sold a total of 3,729 Veracyte common shares. The Form 4 shows weighted average sale prices of $52.7832 per share for 3,200 shares and $53.5504 per share for 529 shares, with detailed price breakdowns available on request.

When did the Veracyte (VCYT) insider sales by Karin Eastham occur?

The insider sales by Karin Eastham occurred on June 18, 2026. Both reported transactions involved Veracyte common stock and were executed as open-market sales, according to the Form 4 transaction details and associated footnotes.

What type of transactions did Veracyte (VCYT) report for Karin Eastham on Form 4?

Veracyte reported open-market sales of common stock by director Karin Eastham. The Form 4 lists transaction code “S,” indicating sales in open-market or private transactions, with no derivative exercises, gifts, or tax-withholding entries disclosed.